Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Avoid YouGov (YOU) by Steve Moore in ShareProphets
- Sell Distil (DIS) by Steve Moore in ShareProphets
- Buy Intermediate Capital Group (ICG) by Goldman Sachs
- Buy Croda International (CRDA) by UBS
- Buy Prudential (PRU) by UBS
- Buy Luceco (LUCE) by Berenberg
- Overweight Oxford Nanopore Technologies (ONT) by Barclays
- Overweight Fevertree Drinks (FEVR) by Barclays
- Buy YouGov (YOU) by Deutsche Bank
- Hold Fevertree Drinks (FEVR) by Deutsche Bank
- Hold BP (BP.) by Mark Hartley in The Motley Fool
- Buy Bellway (BWY) by Citi
- Neutral Kingfisher (KGF) by Goldman Sachs
- Buy Rolls-Royce Holdings (RR.) by Goldman Sachs
- Outperform National Grid (NG.) by Bernstein
- Outperform SSE (SSE) by Bernstein
- Overweight Croda International (CRDA) by Morgan Stanley
- Hold Kingfisher (KGF) by Berenberg
- Sector Perform Mobico Group (MCG) by RBC Capital
- Overweight BP (BP.) by Morgan Stanley
Oxford Biomedica (OXB) Share Price
Health Care Sector
NOTE: This is based on 147 open tips for Oxford Biomedica (OXB)
| Latest Bid : 599.00p | Latest Ask : 602.00p |
| High Today : 608.00p | Low Today : 580.00p |
| This Years High : 913.00p | This Years Low : 232.50p |
| Volume : 276,408 | MKT Cap : £636.3M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Stock Splits and Consolidations
30/05/2018 – Stock Consolidation 50.000:1.000
Oxford Biomedica (OXB) Overview
Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.Oxford Biomedica (OXB) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Jefferies | Premium Only | 2026-03-23 04:35:00 23/03/2026 | 2.19% |
| Buy | Stifel | Premium Only | 2026-03-11 16:30:00 11/03/2026 | -5.75% |
| Buy | Deutsche Bank | Premium Only | 2026-01-09 07:22:00 09/01/2026 | 7.20% |
| Buy | Deutsche Bank | Premium Only | 2026-01-06 07:29:00 06/01/2026 | 7.94% |
| Neutral | JP Morgan | Premium Only | 2025-12-08 04:53:00 08/12/2025 | – |
Oxford Biomedica (OXB) Active Short Positions
| Fund Manager | Position | Date |
|---|---|---|
| Connor, Clark & Lunn Investment Management Ltd | 0.5% | 19/03/2026 |
| Latest Bid : 599.00p | Latest Ask : 602.00p |
| High Today : 608.00p | Low Today : 580.00p |
| This Years High : 913.00p | This Years Low : 232.50p |
| Volume : 276,408 | MKT Cap : £636.3M |
Oxford Biomedica Overview
Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Oxford Biomedica Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Jefferies | Premium Only | 2026-03-23 04:35:00 23/03/2026 | 2.19% |
| Buy | Stifel | Premium Only | 2026-03-11 16:30:00 11/03/2026 | -5.75% |
| Buy | Deutsche Bank | Premium Only | 2026-01-09 07:22:00 09/01/2026 | 7.20% |
| Buy | Deutsche Bank | Premium Only | 2026-01-06 07:29:00 06/01/2026 | 7.94% |
| Neutral | JP Morgan | Premium Only | 2025-12-08 04:53:00 08/12/2025 | – |
Stock Splits and Consolidations
30/05/2018 – Stock Consolidation 50.000:1.000